Adding liposomal irinotecan to 5-fluorouracil and leucovorin can improve outcomes in gemcitabine-refractory, advanced pancreatic cancer, a phase 3 study suggests.
Adding pembrolizumab to lenvatinib does not improve outcomes in patients with advanced hepatocellular carcinoma, results of the LEAP-002 study suggest.